Optimizing Survival and Clinical Outcomes in Metastatic CSCC

Optimizing Survival and Clinical Outcomes in Metastatic CSCC

What Do Landmark Trials Teach Us About the Efficacy and Safety of PD-1 Targeting Immunotherapy in CSCC? Which Patients? When? For How Long? With What Results? -From Trial-Based Data to the Front Lines of Clinical Care in Patients with Advanced Skin Cancer 


Published

Created by

CMEducation Resources symposium

Related Presenters

Karl Lewis, MD

Karl Lewis, MD

Associate Professor of MedicineDivision of Medical OncologyDirector, Cutaneous Oncology ProgramUniversity of Colorado School of Medicine